Baxter Pharmaceutical Solutions LLC

This study aims to find better treatment options for patients with retinal vein occlusion (RVO). Macular edema secondary to retinal vein occlusion can cause patients to have decreased vision. If left untreated, the visual prognosis is usually poor. Aflibercept is already on the market and is used by doctors as a routine clinical treatment for macular edema secondary to RVO. The routine clinical treatment is to give aflibercept injection every 4 weeks. However, frequent follow-up can be a burden for patients. A high-dose 8mg aflibercept formulation has shown efficacy advantages over a 2mg aflibercept formulation in previous studies, and high-dose (8mg) aflibercept can reduce the frequency of administration. The main purpose of this study is to explore the efficacy of high-dose aflibercept in the treatment of macular edema secondary to retinal vein occlusion. Researchers will measure the change in best corrected visual acuity of subjects from the start of the study to 36 weeks of treatment. The differences between subjects receiving high-dose aflibercept and standard treatment with 2mg aflibercept will be compared. To understand the safety data of the study, researchers will count the occurrence of adverse events and serious adverse events from the start of the study to 64 weeks. The study will include a screening phase, a treatment phase, and a study end phase. Each subject will participate in the study for up to 64 weeks. There will be one visit during the screening phase, then approximately every 4 weeks during treatment, and once at the end of the study. During the study, the study doctor and his team will check the subject's eye health: best corrected visual acuity, blood and urine samples, physical examination, vital signs, electrocardiogram, pregnancy test. And a vision quality of life questionnaire.

Primary objective: To describe the safety and tolerability of isavuconazole by observing treatment-emergent adverse events (TEAEs). Secondary objectives: To describe the efficacy of isavuconazole in the treatment of invasive fungal disease (IFD) caused by Aspergillus and other filamentous fungi in Chinese patients. To observe other safety and tolerability characteristics of isavuconazole. To evaluate the pharmacokinetics of isavuconazole in the treatment of IFD caused by Aspergillus and other filamentous fungi in Chinese patients.

Primary objective: To evaluate the anti-tumor activity of odronextamab monotherapy in B-NHL subgroups according to the Lugano response classification for malignant lymphoma, using (ORR) as an indicator: 1. Patients with follicular lymphoma (grade 1-3a) who have relapsed or are refractory after at least 2 lines of systemic therapy. 2. Patients with diffuse large B-cell lymphoma who have relapsed or are refractory after at least 2 lines of systemic therapy. 3. Patients with mantle cell lymphoma who have relapsed or are refractory after (BTK) inhibitor therapy. 4. Patients with (MZL) who have relapsed or are refractory after at least 2 lines of systemic therapy. 5. Patients with other B-NHL subtypes who have relapsed or are refractory after at least 2 lines of systemic therapy. Secondary objective: To evaluate the anti-tumor activity of odronextamab monotherapy in 5 disease-specific cohorts, with the following evaluation indicators: ORR based on Lugano classification and assessed by local investigators; CR; PFS. Overall survival. (DOR) based on Lugano classification. (DCR) based on Lugano classification. To assess the safety and tolerability of odronextamab; (PK); odronextamab immunogenicity. The effects of odronextamab on patient-reported outcomes, including (HRQL), (EORTC QLQ-C30), (FACT-Lym), and (EQ-5D-3L) measurements.